Physician profile
Joshua Killpack
NPI 1164777181
$11,486.68
in general payments reported to CMS, 2019-2025
23 companies · $2,166 in 2025
The $2,166 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,748 · 2022: $1,745 · 2023: $2,221 · 2024: $3,608 · 2025: $2,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,307 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,400 · Travel and Lodging: $1,187 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,307.45 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,400.00 |
| Travel and Lodging | $1,186.78 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $4,694.60 | 2021-2025 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $2,046.82 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $926.03 | 2021-2025 | Nucala, Trelegy Ellipta |
| United Therapeutics Corporation | $721.06 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| Takeda Pharmaceuticals U.S.A., INC. | $436.41 | 2021-2025 | Glassia |
| Astrazeneca Pharmaceuticals Lp | $414.60 | 2021-2025 | Tezspire, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.72 | 2021-2025 | Ofev, Jascayd |
| Baxter Healthcare | $255.52 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| Grifols Shared Services North America, INC. | $240.00 | 2023 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $196.45 | 2022-2023 | |
| Genzyme Corporation | $194.40 | 2021-2024 | |
| Harmony Biosciences LLC | $175.74 | 2023-2025 | Wakix |
| Bayer Healthcare Pharmaceuticals INC. | $166.56 | 2021-2025 | |
| Mylan Specialty L.P. | $151.52 | 2021-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $139.03 | 2022-2025 | Dupixent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $78.62 | 2022-2025 | Arikayce |
| Philips North America LLC | $67.24 | 2021-2023 | |
| Viatris Specialty LLC | $64.47 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $52.56 | 2024-2025 | Winrevair |
| Jazz Pharmaceuticals INC. | $51.76 | 2021-2023 | |
| Lilly USA, LLC | $46.71 | 2025 | Zepbound |
| Fisher & Paykel Healthcare INC | $31.02 | 2023-2024 | Fisher & Paykel Healthcare |
| Novartis Pharmaceuticals Corporation | $12.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Killpack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.